174 related articles for article (PubMed ID: 22537282)
1. Current approaches in tamper-resistant and abuse-deterrent formulations.
Mastropietro DJ; Omidian H
Drug Dev Ind Pharm; 2013 May; 39(5):611-24. PubMed ID: 22537282
[TBL] [Abstract][Full Text] [Related]
2. Abuse-deterrent formulations: part 1 - development of a formulation-based classification system.
Mastropietro DJ; Omidian H
Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):193-204. PubMed ID: 25374404
[TBL] [Abstract][Full Text] [Related]
3. Update on tamper-resistant drug formulations.
Romach MK; Schoedel KA; Sellers EM
Drug Alcohol Depend; 2013 Jun; 130(1-3):13-23. PubMed ID: 23415386
[TBL] [Abstract][Full Text] [Related]
4. Abuse-deterrent and tamper-resistant opioids: how valuable are novel formulations in thwarting non-medical use?
Lourenço LM; Matthews M; Jamison RN
Expert Opin Drug Deliv; 2013 Feb; 10(2):229-40. PubMed ID: 23252692
[TBL] [Abstract][Full Text] [Related]
5. Abuse-deterrent formulations: part 2: commercial products and proprietary technologies.
Mastropietro DJ; Omidian H
Expert Opin Pharmacother; 2015 Feb; 16(3):305-23. PubMed ID: 25421961
[TBL] [Abstract][Full Text] [Related]
6. Ephemeral profiles of prescription drug and formulation tampering: evolving pseudoscience on the Internet.
Cone EJ
Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S31-9. PubMed ID: 16458455
[TBL] [Abstract][Full Text] [Related]
7. Current Impact and Application of Abuse-Deterrent Opioid Formulations in Clinical Practice.
Lee YH; Brown DL; Chen HY
Pain Physician; 2017 Nov; 20(7):E1003-E1023. PubMed ID: 29149148
[TBL] [Abstract][Full Text] [Related]
8. Development and impact of prescription opioid abuse deterrent formulation technologies.
Alexander L; Mannion RO; Weingarten B; Fanelli RJ; Stiles GL
Drug Alcohol Depend; 2014 May; 138():1-6. PubMed ID: 24613631
[TBL] [Abstract][Full Text] [Related]
9. An iterative model for in vitro laboratory assessment of tamper deterrent formulations.
Cone EJ; Giordano J; Weingarten B
Drug Alcohol Depend; 2013 Jul; 131(1-2):100-5. PubMed ID: 23332441
[TBL] [Abstract][Full Text] [Related]
10. Development of opioid formulations with limited diversion and abuse potential.
Fudala PJ; Johnson RE
Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S40-7. PubMed ID: 16564141
[TBL] [Abstract][Full Text] [Related]
11. An overview of prodrug technology and its application for developing abuse-deterrent opioids.
Gudin JA; Nalamachu SR
Postgrad Med; 2016 Jan; 128(1):97-105. PubMed ID: 26615852
[TBL] [Abstract][Full Text] [Related]
12. Laboratory-based testing to evaluate abuse-deterrent formulations and satisfy the Food and Drug Administration's recommendation for Category 1 Testing.
Altomare C; Kinzler ER; Buchhalter AR; Cone EJ; Costantino A
J Opioid Manag; 2017; 13(6):441-448. PubMed ID: 29308590
[TBL] [Abstract][Full Text] [Related]
13. Dosage form design and development.
Allen LV
Clin Ther; 2008 Nov; 30(11):2102-11. PubMed ID: 19108798
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in abuse-deterrent technologies for the delivery of opioids.
Maincent J; Zhang F
Int J Pharm; 2016 Aug; 510(1):57-72. PubMed ID: 27291971
[TBL] [Abstract][Full Text] [Related]
15. The implications of tamper-resistant formulations for opioid rotation.
Pappagallo M; Sokolowska M
Postgrad Med; 2012 Sep; 124(5):101-9. PubMed ID: 23095430
[TBL] [Abstract][Full Text] [Related]
16. Development of tamper deterrent formulations: state of the pharmaceutical industry.
Hamed E; Moe D
Curr Drug Abuse Rev; 2010 Sep; 3(3):139-46. PubMed ID: 21054261
[TBL] [Abstract][Full Text] [Related]
17. Drug-abuse deterrent formulations.
Wick JY
Consult Pharm; 2009 May; 24(5):356-62, 365. PubMed ID: 19555144
[TBL] [Abstract][Full Text] [Related]
18. Methods and predictors of tampering with a tamper-resistant controlled-release oxycodone formulation.
Peacock A; Degenhardt L; Hordern A; Larance B; Cama E; White N; Kihas I; Bruno R
Int J Drug Policy; 2015 Dec; 26(12):1265-72. PubMed ID: 26123898
[TBL] [Abstract][Full Text] [Related]
19. Update on abuse-resistant and abuse-deterrent approaches to opioid formulations.
Webster L
Pain Med; 2009 Jul; 10 Suppl 2():S124-33. PubMed ID: 19691683
[TBL] [Abstract][Full Text] [Related]
20. Formulation considerations for the development of medications with abuse potential.
Mansbach RS; Moore RA
Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S15-22. PubMed ID: 16472940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
